BrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access

Reuters07-08

BrainStorm Cell <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing <a href="https://laohu8.com/S/PASO">Patient Access</a>

BrainStorm Cell Therapeutics Inc. has announced its commitment to proceed with a planned Phase 3b clinical trial, named ENDURANCE, for its treatment NurOwn, targeting amyotrophic lateral sclerosis (ALS). The trial will be conducted under an FDA Special Protocol Assessment $(SPA.UK)$ to generate additional robust data and confirm NurOwn's efficacy and safety in early-stage ALS patients. This development comes as the U.S. Food and Drug Administration (FDA) is set to review a Citizen Petition requesting a new evaluation of the data supporting NurOwn. While BrainStorm was not involved in drafting the petition, the company welcomes the FDA's willingness to reassess the existing data. The results of the Phase 3b trial have not yet been presented, as the trial is planned for future implementation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25930) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2549348549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549348549","market":"nz","top_or_hot":-1,"title":"BrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing <a href=\"https://laohu8.com/S/PASO\">Patient Access</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. has announced its commitment to proceed with a planned Phase 3b clinical trial, named ENDURANCE, for its treatment NurOwn, targeting amyotrophic lateral sclerosis (ALS). The trial will be conducted under an FDA Special Protocol Assessment <a href=\"https://laohu8.com/S/SPA.UK\">$(SPA.UK)$</a> to generate additional robust data and confirm NurOwn's efficacy and safety in early-stage ALS patients. This development comes as the U.S. Food and Drug Administration (FDA) is set to review a Citizen Petition requesting a new evaluation of the data supporting NurOwn. While BrainStorm was not involved in drafting the petition, the company welcomes the FDA's willingness to reassess the existing data. The results of the Phase 3b trial have not yet been presented, as the trial is planned for future implementation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BCLI\">Brainstorm Cell</a> Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25930) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BrainStorm Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing <a href=\"https://laohu8.com/S/PASO\">Patient Access</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BrainStorm Cell Therapeutics Inc. has announced its commitment to proceed with a planned Phase 3b clinical trial, named ENDURANCE, for its treatment NurOwn, targeting amyotrophic lateral sclerosis (ALS). The trial will be conducted under an FDA Special Protocol Assessment <a href=\"https://laohu8.com/S/SPA.UK\">$(SPA.UK)$</a> to generate additional robust data and confirm NurOwn's efficacy and safety in early-stage ALS patients. This development comes as the U.S. Food and Drug Administration (FDA) is set to review a Citizen Petition requesting a new evaluation of the data supporting NurOwn. While BrainStorm was not involved in drafting the petition, the company welcomes the FDA's willingness to reassess the existing data. The results of the Phase 3b trial have not yet been presented, as the trial is planned for future implementation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BCLI\">Brainstorm Cell</a> Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25930) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3X5gny:1","article_id":"2549348549","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549348549","pubTimestamp":1751972482,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on July 08, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCLI":"BrainStorm Cell Therapeutics Inc."},"translate_title":"BrainStorm Cell Therapeutics Inc.宣布ALS治疗NurOwn的3b期试验，重申致力于推进患者用药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCLI":0.9},"content_text":"BrainStorm Cell Therapeutics Inc. Announces Phase 3b Trial for ALS Treatment NurOwn, Reaffirming Commitment to Advancing Patient Access\n\n\n        BrainStorm Cell Therapeutics Inc. has announced its commitment to proceed with a planned Phase 3b clinical trial, named ENDURANCE, for its treatment NurOwn, targeting amyotrophic lateral sclerosis (ALS). The trial will be conducted under an FDA Special Protocol Assessment $(SPA.UK)$ to generate additional robust data and confirm NurOwn's efficacy and safety in early-stage ALS patients. This development comes as the U.S. Food and Drug Administration (FDA) is set to review a Citizen Petition requesting a new evaluation of the data supporting NurOwn. While BrainStorm was not involved in drafting the petition, the company welcomes the FDA's willingness to reassess the existing data. The results of the Phase 3b trial have not yet been presented, as the trial is planned for future implementation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN25930) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549348549","isCrawlerRequest":true}